Ozempic and Wegovy are already transforming how we treat type 2 diabetes and obesity, and from next year another condition affecting millions of people worldwide might be added to the list: Alzheimer’s disease.

Two clinical trials investigating semaglutide, the drug in Ozempic and Wegovy, as a therapy for early Alzheimer’s are expected to conclude in 2025. If the results are positive, it could mark a breakthrough in treating this intractable condition.